Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients

NCT00485979 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: larotaxel (XRP9881)
DRUG: docetaxel
DRUG: trastuzumab

Sponsor

Sanofi